The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
Chemical Compound Review

Diaikron     1-(3-azabicyclo[3.3.0]oct-3- yl)-3-(4...

Synonyms: Diamicron, Gliklazid, Glimicron, Glyclazide, gliclazide, ...
Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of S 852


Psychiatry related information on S 852


High impact information on S 852


Chemical compound and disease context of S 852


Biological context of S 852


Anatomical context of S 852

  • This enhanced effect of insulin after gliclazide treatment was not accompanied by increased monocyte or erythrocyte insulin binding, which suggests that it was due to potentiation of postbinding insulin-sensitive pathways [18].
  • Modalities of gliclazide-induced Ca2+ influx into the pancreatic B-cell [19].
  • The gliclazide-induced increase in 45Ca efflux is thought to reflect a stimulation of 40Ca influx into islet cells; it is suppressed in the absence of extracellular Ca2+ or in the presence of the organic CA2/-antagonist verapamil [19].
  • Gliclazide, a sulphonylurea, was reported to reduce leukocyte adhesion to endothelial cells in hyperglycaemia in vitro, thus suggesting possible selective efficacy of this sulphonylurea in preventing leukostasis in diabetic patients [5].
  • AIMS/HYPOTHESIS: To investigate the tissue specificity of gliclazide for cloned beta-cell, cardiac and smooth muscle ATP-sensitive K-channels (K(ATP) channels) [20].

Associations of S 852 with other chemical compounds


Gene context of S 852


Analytical, diagnostic and therapeutic context of S 852


  1. Postreceptor effects of sulfonylurea on skeletal muscle glycogen synthase activity in type II diabetic patients. Bak, J.F., Schmitz, O., Sørensen, N.S., Pedersen, O. Diabetes (1989) [Pubmed]
  2. Current status of non-insulin-dependent diabetes mellitus (type II): management with gliclazide. Rifkin, H. Am. J. Med. (1991) [Pubmed]
  3. Oral treatment of diabetes mellitus: the contribution of gliclazide. Colwell, J.A. Am. J. Med. (1991) [Pubmed]
  4. Diabetic retinopathy in non-insulin-dependent diabetes mellitus patients: the role of gliclazide. Akanuma, Y., Kosaka, K., Kanazawa, Y., Kasuga, M., Fukuda, M., Aoki, S. Am. J. Med. (1991) [Pubmed]
  5. Effective and selective prevention of retinal leukostasis in streptozotocin-induced diabetic rats using gliclazide. Kinoshita, N., Kakehashi, A., Inoda, S., Itou, Y., Kuroki, M., Yasu, T., Kawakami, M., Kanazawa, Y. Diabetologia (2002) [Pubmed]
  6. Double-blind, randomized, multicentre study of the efficacy and safety of gliclazide-modified release in the treatment of Chinese type 2 diabetic patients. Lu, C.H., Chang, C.C., Chuang, L.M., Wang, C.Y., Jiang, Y.D., Wu, H.P. Diabetes, obesity & metabolism. (2006) [Pubmed]
  7. Gliclazide directly inhibits arginine-induced glucagon release. Cejvan, K., Coy, D.H., Holst, J.J., Cerasi, E., Efendic, S. Diabetes (2002) [Pubmed]
  8. Relative hyperproinsulinemia of NIDDM persists despite the reduction of hyperglycemia with insulin or sulfonylurea therapy. Rachman, J., Levy, J.C., Barrow, B.A., Manley, S.E., Turner, R.C. Diabetes (1997) [Pubmed]
  9. Release of amylin from perfused rat pancreas in response to glucose, arginine, beta-hydroxybutyrate, and gliclazide. Inoue, K., Hisatomi, A., Umeda, F., Nawata, H. Diabetes (1991) [Pubmed]
  10. Favorable effects of pioglitazone and metformin compared with gliclazide on lipoprotein subfractions in overweight patients with early type 2 diabetes. Lawrence, J.M., Reid, J., Taylor, G.J., Stirling, C., Reckless, J.P. Diabetes Care (2004) [Pubmed]
  11. Gliclazide modified release. McGavin, J.K., Perry, C.M., Goa, K.L. Drugs (2002) [Pubmed]
  12. Efficacy and safety of gliclazide in the treatment of non-insulin-dependent diabetes mellitus: a Canadian multicenter study. Mailhot, J. Clinical therapeutics. (1993) [Pubmed]
  13. Increased fibrinolytic potential induced by gliclazide in types I and II diabetic patients. Gram, J., Jespersen, J. Am. J. Med. (1991) [Pubmed]
  14. Pathogenesis of diabetic microangiopathy: an overview. Barnett, A.H. Am. J. Med. (1991) [Pubmed]
  15. Vascular action of the hypoglycaemic agent gliclazide in diabetic rabbits. Pagano, P.J., Griswold, M.C., Ravel, D., Cohen, R.A. Diabetologia (1998) [Pubmed]
  16. The direct effect of hypoglycaemic sulphonylureas on myocardial contractile force and arterial blood pressure. Pogátsa, G., Dubecz, E. Diabetologia (1977) [Pubmed]
  17. Antiaggregatory activity of hypoglycaemic sulphonylureas. Siluk, D., Kaliszan, R., Haber, P., Petrusewicz, J., Brzozowski, Z., Sut, G. Diabetologia (2002) [Pubmed]
  18. Gliclazide therapy is associated with potentiation of postbinding insulin action in obese, non-insulin-dependent diabetic subjects. Ward, G., Harrison, L.C., Proietto, J., Aitken, P., Nankervis, A. Diabetes (1985) [Pubmed]
  19. Modalities of gliclazide-induced Ca2+ influx into the pancreatic B-cell. Lebrun, P., Malaisse, W.J., Herchuelz, A. Diabetes (1982) [Pubmed]
  20. Differential sensitivity of beta-cell and extrapancreatic K(ATP) channels to gliclazide. Gribble, F.M., Ashcroft, F.M. Diabetologia (1999) [Pubmed]
  21. Sulphonylurea stimulates glucose uptake in rats through an ATP-sensitive K+ channel dependent mechanism. Pulido, N., Casla, A., Suárez, A., Casanova, B., Arrieta, F.J., Rovira, A. Diabetologia (1996) [Pubmed]
  22. Sulphonylureas in vitro do not alter insulin binding or insulin effect on amino acid transport in rat hepatocytes. Dolais-Kitabgi, J., Alengrin, F., Freychet, P. Diabetologia (1983) [Pubmed]
  23. Improvement in glucose-induced insulin secretion in diabetic rats after long-term gliclazide treatment: a comparative study using different models of non-insulin-dependent diabetes mellitus induced by neonatal streptozotocin. Portha, B., Serradas, P. Am. J. Med. (1991) [Pubmed]
  24. Insulinotropic effects of hypoglycaemic and hyperglycaemic sulphonamides: the ionophoretic hypothesis. Couturier, E., Malaisse, W.J. Diabetologia (1980) [Pubmed]
  25. Normalization of plasma lipid peroxides, monocyte adhesion, and tumor necrosis factor-alpha production in NIDDM patients after gliclazide treatment. Desfaits, A.C., Serri, O., Renier, G. Diabetes Care (1998) [Pubmed]
  26. Advanced glycation end-products increase monocyte adhesion to retinal endothelial cells through vascular endothelial growth factor-induced ICAM-1 expression: inhibitory effect of antioxidants. Mamputu, J.C., Renier, G. J. Leukoc. Biol. (2004) [Pubmed]
  27. Gliclazide increases insulin receptor tyrosine phosphorylation but not p38 phosphorylation in insulin-resistant skeletal muscle cells. Kumar, N., Dey, C.S. J. Exp. Biol. (2002) [Pubmed]
  28. Development of macroangiopathy in sand rats (Psammomys obesus), an animal model of non-insulin-dependent diabetes mellitus: effect of gliclazide. Marquié, G., Hadjiisky, P., Arnaud, O., Duhault, J. Am. J. Med. (1991) [Pubmed]
  29. Preventive effect of gliclazide on experimental atherosclerosis in rabbits. Marquié, G. Diabetologia (1978) [Pubmed]
  30. Comparison of capillary electrophoresis with HPLC for diagnosis of factitious hypoglycemia. Paroni, R., Comuzzi, B., Arcelloni, C., Brocco, S., de Kreutzenberg, S., Tiengo, A., Ciucci, A., Beck-Peccoz, P., Genovese, S. Clin. Chem. (2000) [Pubmed]
  31. Measurement of gliclazide in plasma by radial compression reversed-phase liquid chromatography. Charles, B.G., Ravenscroft, P.J. Clin. Chem. (1984) [Pubmed]
WikiGenes - Universities